Analyst Kyle Mikson CFA from Canaccord Genuity maintained a Hold rating on Repligen (RGEN – Research Report) and keeping the price target at $150.00.
Kyle Mikson CFA’s rating is based on a combination of factors that suggest Repligen’s stock is fairly valued at present. The company’s first quarter of 2025 results were solid, with revenue and adjusted earnings slightly exceeding estimates, and a positive outlook on order growth from key markets like CDMOs and pharma companies. However, despite these encouraging signs, the company’s core growth outlook for 2025 remains unchanged, and the valuation appears somewhat high relative to current performance.
While Repligen has raised its revenue guidance for 2025, reflecting contributions from recent acquisitions, the adjustments in operating and EBITDA margins suggest a cautious approach. The minimal impact of tariffs and the potential for revenue tailwinds due to pricing increases are positive, yet the unchanged core growth and margin forecasts indicate limited upside potential. Therefore, while the company’s execution on its growth strategy is commendable, the valuation levels lead to a Hold rating, as the stock seems to be priced appropriately given the current market conditions.
Mikson CFA covers the Healthcare sector, focusing on stocks such as Illumina, Repligen, and Akoya Biosciences. According to TipRanks, Mikson CFA has an average return of -15.9% and a 26.19% success rate on recommended stocks.
In another report released yesterday, Jefferies also maintained a Hold rating on the stock with a $160.00 price target.